Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab DDI Study in Psoriasis
NCT02397382Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 36, Time to Reach Maximum Concentration at Day 36 and 4 more. Started Jun 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02397382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397382.